181 results about "Diagnoses diseases" patented technology

Systems and methods for computer modeling in medicine. A sort of period table of medical models is described for personalized diagnostics, prognostics and therapeutics, including at least 80 major categories of medical models. Generative artificial intelligence and geometric deep learning techniques, and algorithms including 2D and 3D graph machine learning and GenAI algorithms, are described, tailored and applied to diagnostic disease description, prognostic prediction and therapeutic development and management, including generation of novel synthetic drugs. The AI and machine learning techniques and algorithms are applied to understand each individual's genetic, RNA and protein anomalies that represent the source of many unique patient diseases. AI-enabled software agents assist physicians and researchers in building patient medical models. Several personalized medicine applications of individualized medical modeling include cardiovascular disease, cancer, neurological disorders, immune system disorders and genetic diseases.

By producing the proper wave interference using superimposed angularly separate waves that overlap with the proper time-phase relationship (called “Time-Correlated Standing-wave Interference”), wave energy is amplified (by “Coherent Intensity Amplification”) and teleported to precise locations. For instance, in one application, energy is teleported to one or more areas within a living body for such therapeutic applications as destroying cancer cells or plaques within arteries. A system implementing this technique creates amplified constructive interference at one or more selected disease locations, while producing destructive interference at surrounding locations. In this application example, the technique allows energy to be “teleported” to tumor cells, plaques, or other diseased cells, for instance, to destroy them, while surrounding healthy cells receive virtually no energy, obviating collateral damage from the treatment. The same method can be used to diagnose disease by detecting energy teleported to different locations.

The present invention provides CD40 agonist antibodies having significantly higher CD40 activating activity in the presence of simultaneous tumor associated antigen (TAA) binding than in the absence of such simultaneous binding. Such TAA-dependent CD40 agonism results in a significant increase in therapeutic index, reducing or completely eliminating adverse events that are typically associated with CD40 activation, such as cytokine release syndrome or hepatotoxicity. Also provided are bispecific and multispecific antibodies and polypeptides such as 5T4 / CD40, such as chimeric antigen receptors, which are optionally incorporated into the antibodies with anti-TAA units. Methods of using these antibodies or polypeptides to treat and diagnose diseases, such as cancer, are also provided.

The present invention relates to a method, preferably a computer-implemented method, and to an apparatus for generating at least one intermediate cellular state of a cellular state evolution from an initial cellular state to a corresponding advanced cellular state. The present invention also relates to a computer program for generating at least one intermediate cellular state and to a non-transitory computer readable data medium storing the computer program. Moreover, the present invention relates to a method and to an apparatus for training a model for generating at least one intermediate cellular state of a cellular state evolution from an initial cellular state to a corresponding advanced cellular state. The present invention also relates to a computer program for training a model for generating at least one intermediate cellular state and to a non-transitory computer readable data medium storing the computer program. Furthermore, the present invention relates to a method for diagnosing a disease and forecasting patients' future clinical outcome making use of the method for generating at least one intermediate cellular state. Moreover, the present invention relates to an in-vitro method for transforming the identity of a cell.

The invention discloses a multi-modal enhanced representation collaborative learning pneumonia image recognition method, which comprises the following steps of: aiming at chest radiograph image data, respectively extracting visual modal features and text modal features, and generating rich feature representation fused with context semantics through a multi-modal feature coding strategy; a collaborative learning mechanism is adopted, complementarity of visual and text features is combined, the model is guided to carry out feature optimization and decision reasoning, and robustness and interpretability of the model are improved; in the classification reasoning stage, multi-modal auxiliary information is utilized to refine pathological region features, and fine-grained differences are effectively captured; and through an auxiliary information constraint mechanism, the recognition capability of the model on a tiny pathological mode is enhanced, and the pneumonia classification accuracy and generalization capability are improved. The method can be widely applied to computer vision tasks in the fields of medical image auxiliary diagnosis, disease detection and the like.

To provide a system that enables patients to receive disease diagnosis and appropriate medical department recommendations by inputting images of affected areas and symptoms.SOLUTION: A system comprises: means for inputting images of affected areas and symptoms; means for diagnosing diseases using artificial intelligence; and means for recommending appropriate medical departments.SELECTED DRAWING: Figure 1

The present disclosure provides oligonucleotides comprising at least one radical of a central nervous system receptor ligand at a nucleobase, the 2' position of a nucleoside, or the 3' position of a nucleoside. The present disclosure also provides pharmaceutical compositions and kits comprising said oligonucleotides, methods of delivering said oligonucleotides, methods of modulating the activity of a protein using such oligonucleotides, and methods of treating, preventing, or diagnosing diseases (e.g., central nervous system diseases, neurodegenerative diseases, and neurocognitive diseases) in a. subject in need thereof using said oligonucleotides or pharmaceutical compositions thereof. The present disclosure also provides oligonucleosides that may be useful for making the oligonucleotides.

According to the ultrasonic imaging area array probe based on the array elements arranged in the regular hexagon mode and the imaging method, the array elements are arranged in the regular hexagon mode, each array element has the transmitting and receiving functions in three directions, and composite imaging with higher quality can be achieved in cooperation with unique addressing and signal processing algorithms. Therefore, the resolution ratio and the contrast ratio of an ultrasonic image are greatly improved, a doctor can see details of tissues and organs more clearly, diseases can be diagnosed more accurately, and the method has obvious advantages especially in the aspects of observation of minimal lesions, complex structures, blood flow signals and the like. The addressing technology provided by the invention can realize combined imaging of signals in multiple directions, so that the imaging angle is increased, the effective coverage range is expanded, and the imaging blind area is reduced. The method is particularly important in imaging of organs or lesions in complex shapes, information can be obtained more comprehensively, key details are prevented from being omitted, and a more complete image basis is provided for clinical diagnosis.

The present invention concerns the use of aprotic polar solvents and an ionization stabilizing agent to prepare stable therapeutic formulations of levothyroxine by dissolving levothyroxine in an aprotic polar solvent system that can then be used to treat, prevent, and / or diagnose certain diseases and disorders in humans and veterinary animals by administration of the formulation thereto. In certain embodiments, the invention is directed to formulations comprising levothyroxine, and optionally one or more additional therapeutic agents, dissolved in an aprotic polar solvent system, such as a DMSO / water admixture comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent. The invention also provides methods of use of such formulations in treating, preventing, and / or diagnosing diseases and disorders, and methods of manufacturing such formulations.

An active electro-physiological system and method are provided. The present technology is directed to use a multi electrode array (MEA) chip to emit a temporal-spatial patterned stimulation signal data to a neuronal tissue (e.g., a brain organoid) and receive response signal data from the neuronal tissue. The system actively determines a representational function of a neuronal tissue based on correlation between temporal-spatial patterned stimulations and responses. The system performs functional phenotyping according to chemical and / or biological reagents as an external input in contact with the neuronal tissue. The active electro- physiological system diagnoses a disease by using cells and tissues of a clinical patient as the neuronal tissue placed in the MEA chip and / or as an external input to the neuronal tissue. The active electro-physiological system further performs biocomputing by training the neuronal tissue to classify input data and / or predict output data according to a representational function of the neuronal tissue.

Disclosed is a sterile MRI probe infusion device for preparing and administering a hyperpolarized MRI probe to a patient in need thereof. The device includes one or more reaction chambers, where a hyperpolarized MRI probe is prepared, separated from the reaction mixture, concentrated, and a solution of suitable concentration for administration to a patient is prepared. Also disclosed is a method of preparing and administering a hyperpolarized MRI probe by the use of the device to a patient in need thereof for diagnosing stages of a disease or an adverse condition or monitoring progress of a treatment of the patient having a disease or an adverse condition.

Described herein are means for implementing annotation-efficient deep learning models utilizing sparsely-annotated or annotation-free training, in which trained models are then utilized for the processing of medical imaging. An exemplary system includes at least a processor and a memory to execute instructions for learning anatomical embeddings by forcing embeddings learned from multiple modalities; initiating a training sequence of an AI model by learning dense anatomical embeddings from unlabeled data, then deriving application-specific models to diagnose diseases with a small number of examples; executing collaborative learning to generate pretrained multimodal models; training the AI model using zero-shot or few-shot learning; embedding physiological and anatomical knowledge; embedding known physical principles refining the AI model; and outputting a trained AI model for use in diagnosing diseases and abnormal conditions in medical imaging. Other related embodiments are disclosed.

The invention discloses a primer probe group and a kit for joint detection of mycoplasma genitalium, ureaplasma urealyticum and chlamydia trachomatis, and belongs to the technical field of molecular biological detection. The primer probe group comprises a primer probe group A for directly detecting a mycoplasma genitalium mgpB gene, a primer probe group B for directly detecting a ureaplasma urealyticum ureB gene and a primer probe group C for directly detecting a chlamydia trachomatis ompA gene; the kit comprises a PCR (Polymerase Chain Reaction) reaction solution and the primer probe group. Nucleic acid extraction is not needed, the detection cost is greatly reduced, the experiment time is shortened, meanwhile, the specificity and accuracy are still guaranteed, meanwhile, the sensitivity is improved, and the method has wide application prospects in the fields of non-gonococcal genital tract infection main pathogen detection, infertility and prenatal and postnatal care screening and the like. And the kit has important significance on clinical diagnosis, early treatment and prevention of diseases, prevalence and the like.

The present invention relates to MSLN-specific binding constructs comprising a designed ankyrin repeat domain with binding specificity for MSLN and a chelator capable of bonding to a radionuclide, as well as to such MSLN-specific binding constructs comprising a half-life extending moiety with binding specificity for serum albumin. The invention further relates to methods of producing such radio-labelled MSLN-specific binding constructs, pharmaceutical compositions comprising such constructs, and the use of such constructs or pharmaceutical compositions in methods for treating, imaging or diagnosing diseases, such as cancer.

The invention relates to the technical field of medical systems, in particular to an intelligent diagnosis auxiliary system based on informatization planning, which comprehensively collects inspection operation parameters and patient physique information and covers data in multiple aspects from inspection process details to patient individual physique characteristics. The data are mapped to a test method-interference factor relation network through a knowledge graph, the influence of test operation interference and patient physique interference on diagnosis can be comprehensively analyzed, the influence condition of interference parameters is quantified by adopting a natural constant power formula in test process anomaly analysis and physique-to-diagnosis disease anomaly influence analysis, and the diagnosis accuracy is improved. The non-linear quantification mode better accords with the actual relation between interference and influence in a medical examination operation scene, the influence degree of the examination process and the patient physique on diagnosis can be more accurately evaluated, and then a more reliable basis is provided for diagnosis.

The present application provides constructs comprising an antibody moiety that specifically binds to a mesothelin extracellular domain. Also provided are methods of making and using these constructs, and uses thereof, including treating and diagnosing diseases.

The present invention relates to a nucleic acid nanostructure comprising at least one scaffold chain and a plurality of staple chains wherein the nanostructure, preferably the at least one scaffold chain, comprises at least one nucleic acid sequence encoding a gene. The invention further relates to a composition comprising the nucleic acid nanostructure, and to a set of nucleic acid sequences or a set of plasmids encoding a nucleic acid nanostructure. Furthermore, the present invention relates to a nucleic acid nanostructure or a composition comprising a nucleic acid nanostructure for use in a medicament, preferably in a method for preventing, treating and / or diagnosing a disease or condition. The invention also relates to a method for expressing a gene from a nucleic acid nanostructure, and to the use of a nanostructure or composition for gene expression.

The methods and systems disclosed herein can improve the ability to analyze genomic material. The methods provided herein can examine transcription factor binding site accessibility to diagnose disease or monitor the progression of disease in a subject.

The embodiment of the invention provides a multi-role adaptive interaction method and system based on a stomatology knowledge base, and the method comprises the steps: recognizing a query role when a query signal is received, and obtaining the query content; calling a preset query engine matched with the query role, accessing a pre-constructed knowledge base according to the currently called query engine and the query content, and obtaining a differential diagnosis set containing a plurality of diseases with a sorting relationship; and performing multi-dimensional differential diagnosis reasoning on the diseases in the differential diagnosis set one by one according to the sorting relationship, correspondingly evaluating the comprehensive confidence coefficient of the reasoning result, and when the comprehensive confidence coefficient is not less than a preset threshold value, taking the corresponding disease as a diagnosis disease, and outputting a query report matched with the query role. According to the invention, doctors can be assisted to make professional clinical decisions, and convenient oral common sense popularization services can be provided for patients.

The present invention relates to a system and a device for diagnosing disease by using artificial intelligence, and an operating method thereof. The method may comprise the steps of: acquiring an interpretation report in which interpretation results of a medical image is recorded in a non-standardized form, a prompt including a user request to be input into an artificial intelligence model for disease diagnosis, and a template for standardizing and storing information necessary for the disease diagnosis; generating, on the basis of the prompt, the template and the interpretation, report input information for diagnosing the medical image; extracting diagnosis information necessary for the disease diagnosis from the input information; recording the extracted diagnosis information in the template; transmitting the diagnosis information recorded in the template to a designated server including the artificial intelligence model; receiving diagnosis results of the medical image from the server; and providing the received diagnosis result. The present invention can improve the speed, accuracy and / or objectivity of disease diagnosis. In addition, the present invention can provide an effective treatment method on the basis of the diagnosis results. Therefore, the present invention can improve the efficiency of disease diagnosis.

The present invention relates to novel biomarkers and combinations thereof for cell type-specific and / or organ-specific extracellular vesicles, particularly brain-specific and / or neuron-specific extracellular vesicles. The present invention also relates to methods for the isolation and / or enrichment of cell type-specific and / or organ-specific extracellular vesicles, methods for the identification of extracellular vesicles derived from cells, and methods for diagnosing or prognosticating a disorder, such as a neurodegenerative disorder, using cell type-specific and / or organ-specific extracellular vesicles. Compositions in the form of kits of reagents for detecting cell type-specific and / or organ-specific extracellular vesicles are also provided.

A method of performing bisulfite sequencing on ultrashort single-stranded cell-free DNA (uscfDNA) and mononucleosomal cell-free DNA (mncfDNA) is described as well as methods of using the methylation profile of uscfDNA and / or mncfDNA for detecting biomarkers and diagnosing diseases and disorders.

Anti-4-1BB single domain antibodies and polypeptides, e.g., bispecific antibodies and chimeric antigen receptors comprising these single domain antibodies, are provided. These antibodies, including humanized antibodies, exhibit superior activity and are suitable for use in various bispecific antibody formats. Methods of using the antibodies or polypeptides to treat and diagnose diseases, e.g., cancer, are also provided.

Methods and products for discovering disease biomarkers and diagnosing disease are provided. RNA or cDNA samples are typically dominated by sequences from highly expressed genes, which can negatively impact the analysis of the samples. The present invention provides methods and products for preparing a treated nucleic acid sample having a more uniform sequence distribution, which can then be analyzed to find and detect disease biomarkers. Methods of protecting RNA in a blood sample are also provided. These methods can be combined to further improve the ability to find and detect disease biomarkers.

The invention provides a DRG group-entering recommendation method and device based on a large model, equipment and a medium, and the method comprises the steps: carrying out the disease extraction of a medical record of a to-be-recommended patient based on a medical model, obtaining a diagnosed disease, and carrying out the main diagnosis selection based on the diagnosed disease, a diagnosis disease list and the medical record, and obtaining a main diagnosis disease; dRG grouping recommendation is carried out based on main diagnosis diseases, the DRG grouping recommendation result of the patient to be recommended is obtained, the defects that current DRG grouping is poor in clinical adaptability, important information is prone to being missed, and accuracy and reliability are insufficient are overcome, diagnosis with insufficient basis is eliminated from the perspective of diagnosis treatment through a medical model, and therefore a diagnosis disease list is optimized and perfected, and the diagnosis efficiency is improved. On the basis, main diagnosis selection and DRG grouping recommendation are carried out according to medical records, accurate and reliable DRG grouping can be achieved, and the method has extremely high interpretability and adaptability in the clinical use process and can meet actual application requirements.

The all-in-one cartridge (100) for on-site diagnosis provided in the present disclosure relates to an integrated cartridge capable of sample solution injection and detection. The cartridge is equipped with a sample injection cap (13), a sample injection port (14), a tip (12), a 2D barcode (15), a sample chamber (22), a buffer chamber (23), a mixing chamber (25), a washing chamber (26), and a PCR chamber (28) for performing PCR. The cartridge (100) can be used for molecular diagnosis, and a diagnostic device therefor can be selectively used for molecular diagnosis, immunodiagnosis and rapid diagnosis.

A method of automated diagnosis of disease database entities includes receiving a case processing request via an input application programming interface (API), extracting image data from the case processing request including at least one medical scan image of the patient, selecting at least a portion of the medical scan image(s) according to specified selection criteria, normalizing the selected at least a portion of the medical scan image(s), supplying the selected at least a portion of the medical scan image(s) to a machine learning model to generate a target medical condition prediction output, wherein the target medical condition prediction output is indicative of a likelihood that a patient will experience a future disease diagnosis event corresponding to the target medical condition, and automatically transmitting the target medical condition prediction output as an electronic transmission via an output API to a provider system associated with the patient.

The invention relates to the field of disease treatment, in particular to an anti-B7-H3 antibody or an antigen binding fragment thereof, a nucleic acid molecule encoding the antibody or the antigen binding fragment, and a method for preparing the antibody or the antigen binding fragment. The anti-B7-H3 antibody or the antigen binding fragment of the anti-B7-H3 antibody has high specificity and high affinity to B7-H3. The invention further relates to the use of said antibodies or antigen-binding fragments thereof in the treatment and diagnosis of disease.

Systems and methods for diagnosing a disease, a condition, or a characteristic in a subject are provided. In one such method, a future severity of an infection or inflammatory disease in a subject afflicted with the infection or inflammatory disease is predicted by obtaining a plurality of methylation levels. Each respective methylation level in the plurality of methylation levels represents a corresponding methylation level at a CpG site at a corresponding genetic locus in a plurality of genetic loci in a biological sample obtained from the subject. The plurality of methylation levels are inputted into a model comprising a plurality of parameters, where the model applies the plurality of parameters to the plurality of methylation levels to generate as output from the model an indication as to future severity of an infection or inflammatory disease in the subject.

Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) domain with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, methods of making thereof, and uses as therapeutic molecules for treatment and diagnosis of diseases and disorders.